Histological and mucoadhesion studies on transpalatal mucoadhesive disks of Rosiglitazone maleate by Shakya, Ashok K. et al.
International Journal of Drug Delivery 3 (2011) 456-464 
http://www.arjournals.org/index.php/ijdd/index 
 
Original Research Article 
               
ISSN: 0975-0215 
Histological and mucoadhesion studies on transpalatal mucoadhesive disks 
of Rosiglitazone maleate 
Ashok K. Shakya1,   N.V. Satheesh Madhav1,  Pragati Shakya1 
 
*Corresponding author: 
 
1. Pragati Shakya 
Faculty of pharmacy, Integral 
university Basha Dashauli 
Kursi Road lucknow  
226026, India. 
pragatimpharm@yahoo.co.in, 
Tel. No. +919453604762, 
Fax No.  0522 -2890809 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
The present research is aimed to develop a mucoadhesive drug 
delivery system exhibiting a unique combination of mucoadhesion 
and controlled drug release in systemic manner to prolong residence 
in the soft palatal mucosa using rosiglitazone maleate as a model 
drug. In this study, a mucoadhesive disks formulation for palatal 
delivery were designed using a simplex lattice design with a mixture 
of various mucoadhesive polymers (Cp, SCMC, or HPMC, Guar 
gum and DPP), followed by optimization of the evaluation 
parameters was employed to get final optimized formulation. In vitro 
mucoadhesion and mucoretentability property of the formulated 
disks were examined and histological study was carried out to 
examine an ex-vivo interaction between the disks and tissue. The 
optimized F-11 composition showed a force of adhesion (N) > 3   
and a mucoadhesion time >12 hours with zero order release profile 
as best fit model closer to the target release profile and followed 
anomalous mediated release of rosiglitazone maleate .The different 
concentration of mucoadhesive polymer significantly affects the 
drug release rate, force of adhesion and mucoretentability 
characteristics of the disks. No more histological changes were 
observed in the excised palatal mucosa after 12 h contact with the 
disks. This kind of disks extends the residence time of a dosage form 
at a particular site and controlling the release of drug in systemic 
manner from the dosage form and useful especially for achieving 
controlled plasma level of the drug as well as improving 
bioavailability with reduced side effects. 
Keywords: Rosiglitazone maleate; Mucoadhesive disks; Force of 
adhesion; Date Palm Polysacchride (DPP), Transpalatal route. 
Introduction 
Oral administration is the most convenient, 
widely utilized, and preferred route of drug 
delivery for systemic action. However, when 
administered orally, many therapeutic agents are 
subjected to extensive presystemic elimination by 
gastrointestinal degradation and/or first pass 
hepatic metabolism [1-2], as a result of which 
low systemic bioavailability and shorter duration 
of therapeutic activity and/or formation of 
inactive or toxic metabolites have been reported 
[3-4]. Further, the quick passage of dosage forms 
through the absorptive segment of GIT often 
leads to unutilized drug, particularly in case of 
extended delivery of narrow absorption window 
drugs [5]. Much attention has been focused, 
recently on targeting a drug delivery system to a 
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particular region of the body for extended period 
of drug release, not only for local targeting of 
drugs but also for the better control of systemic 
delivery. The concept of mucoadhesion was 
introduced into controlled drug delivery in the 
early 1980s. Mucoadhesives are synthetic or 
natural polymers, which interact with the mucus 
layer covering the mucosal epithelial surface and 
mucin constituting a major part of the mucus. 
Drug delivery using mucoadhesive dosage form 
via transmucosal route, bypasses hepato-
gastrointestinal first pass elimination associated 
with oral administration, thereby increases the 
bioavailability and produces longer therapeutic 
effect [6-7]. Rosiglitazone - a potent, novel 
antidiabetic agent is used in management of type-
II diabetes mellitus. After 8 to 12 weeks of 
Rosiglitazone monotherapy, the dose may be 
doubled in case of insufficient response and this 
leads to higher incidence of dose dependent side 
effects [8]  such as gastro-intestinal disturbances, 
headache, altered blood lipids, oedema, 
hypoglycaemia [9]. Further, adverse events of 
clinical significance which are reported 
frequently with conventional instant release 
dosage forms of the drug are edema, anemia, and 
weight gain [10]. Clinical studies showed that 4-
mg twice-per-day regimen compared to 8 mg 
once a day provides statistically greater 
improvement in glycemic control [11]. Thus, 
there is a need to maintain Rosiglitazone at its 
steady state plasma concentration which makes 
Rosiglitazone maleate as suitable candidate for 
mucoadhesive transpalatal drug delivery system. 
Hence, this study was carried out to formulate 
and evaluate mucoadhesive transpalatal dosage 
form of rosiglitazone maleate as a model drug 
and optimize the formulation parameters to 
finally get optimized formulations which would 
control blood glucose level for prolonged period 
to achieve better glycemic control over 
immediate-release dosage formulation.  In the 
literature, very few reports of RZM formulations 
such as carbopol-based mucoadhesive tablet [12] 
and intragastric floating sustained-release tablet 
[13] based on hydrodynamically balanced system 
are available. The efficacy of carbopol-based 
mucoadhesive dosage is restricted by its 
nonspecific mucoadhesion and mucin turnover in 
GIT [14]. Single-unit floating dosage form like 
tablet is associated with all-or-nothing emptying 
nature or dose-dumping phenomenon. However, 
no attempt has been reported yet to develop 
mucoadhesive transpalatal of rosiglitazone 
maleate for its controlled- release drug delivery 
having sufficient bioadhesive strength, 
bioadhesion time, and desired release profile.  
Palatal route offers many advantages over 
conventional routes of delivery with an improved 
bioavailability due to the avoidance of 
degradation in the gastrointestinal tract and 
hepatic first-pass metabolism [15-16]. 
 
Materials and methods 
Rosiglitazone Maleate was received as a gift 
sample from Sun Pharma Ltd, Jammu.  Carbopol 
934 (Loba cheme Pvt. limited, Mumbai), H P M 
C – K4M  (Central drug house, Delhi) , Date 
Palm fruit pulp isolated from Phoenix sylvestris 
taken from local market (Authentified from 
National Botanical Research Institute, Lucknow), 
carboxymethyl cellulose sodium salt (high 
viscosity) were purchased from Fluka Chemie 
GmbH CH-9471 Buchs.   Mannitol (Central drug 
house, Delhi) and other chemicals used were 
procured commercially and were used as 
received. 
 
Dose calculation 
For controlled drug release up to 12h, the total 
dose of drug required was calculated based on the 
fact that the conventional dose was calculated 
using the following equation [17]. For 
Rosiglitazone maleate:  Dt= Dose 
(1+0.693×12/3.5), Dt =6.752mg Rosiglitazone 
and 8.943mg of Rosiglitazone maleate is 
equivalent to 6.752mg Rosiglitazone. 
 
Dt= Dose (1+0.693×t/t ½), Dt =Total dose, 
Dose=Immediate release dose, t=Total time 
period for which controlled release is required, 
t½ = Half life of drug.  
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Preparation of Discs by Direct Compression 
Formulations were developed following a 
simplex lattice design [18] after setting the 
individual excipient levels through 
preformulation studies. We developed a series of 
formulations mentioned in the table1. Discs were 
prepared by directly compressing 150 mg of 
finely powdered mixtures of bioadhesive 
polymers, Rosiglitazone Maleate and other 
excipients in the ratios given in Table I at a 
pressure of 5,000 kg for 15 s using the infrared 
hydraulic press (Shimadzu, Japan). The 50 discs 
of each batch no.  (F1- F15) were prepared using 
the 13-mm diameter set [19].  
 
Drug excipient compatibility study 
Binary mixture approach was used to screen the 
compatibility of drug with selected polymers. 10 
mg drug was mixed thoroughly with the selected 
excipients to form physical mixtures. The 
physical mixtures were then kept in sealed vials 
at 55°C/ 25 % RH for 2 weeks in the ratio 1:1 and 
1:10 and the vials examined daily at regular 
interval for discoloration, caking, liquefaction.  
After 2 weeks the mixtures were subjected to thin 
layer chromatographic studies of 2 mcg/ml drug 
content by using silica gel 60 G254 as stationary 
phase and Toluene: ethyl acetate: methanol: 
Diethylamine (6:3:0.5:0.15) as mobile phase. The 
Rf value was determined and compared with the 
Rf value of the pure drug [20].  
 
Evaluation of Mucoadhesive Palatal Discs 
Friability- A sample of ten formulation was 
selected. The sample was accurately weighed and 
placed in the drum of tablet friability apparatus 
(Roche friabilator -Model DFI-1, Veego, 
Bombay, India). The samples underwent 25 rpm, 
for 4 min, and were then reweighed. This process 
was repeated for all formulations and the 
percentage friability was calculated using the 
following equation [21].  
F=   (W1-W2) × 100 
            W1 
F, the percentage weight loss and W1 and W2 are 
the initial and final discs weights, respectively. If 
obviously cracked, cleaved, or broken discs are 
present in the disc sample after tumbling, the 
sample fails the test. A maximum weight loss of 
not more than 1% of the weight of the discs being 
tested is considered acceptable. This procedure 
was used to determine friability of formulations 
prepared by direct compression 
 
Disc Thickness 
The thickness of the buccal discs was determined 
using a digital caliper. The thickness of six discs 
was measured and the average thickness was 
determined. 
 
Drug Content Uniformity 
Six formulations of each batch no. (F1-F11) were 
dissolved in 50 mL phosphate buffer (pH 7.4).  
and filtered through whatman filter paper. (110 
mm Φ) The amount of drug in each disk was 
determined uv spectrophotometrically at there 
λmax. 242nm. 
 
Weight Uniformity 
Six formulations were randomly selected and 
accurately weighed using an electronic balance. 
The results are expressed as the mean values of 
six determinations. 
 
In Vitro Mucoadhesive Strength Measurement 
MS of selected polymer with palatal mucosa was 
measured using a modified 2-arm balance [22]. 
Goat palatal tissue were obtained from a local 
slaughterhouse and stored in Krebs buffer upon 
collection using ice box. The experiments were 
performed within hours of procurement of tissue. 
The tissue was fixed to the stainless steel piece 
with cynoacrylate adhesive and then placed in a 
beaker by facing the mucosal surface upperside. 
Krebs solution was added into the beaker up to 
the surface of the palatal mucosa to maintain 
palatal mucosal viability during the experiments 
and aeration maintained throughout the 
experiment by using aerator pump. The prepared 
polymer disc was attached to the upper clamp of 
the apparatus and then the pan was raised slowly 
until contact between mucosa and disc was 
established. A preload of 50 g was placed on the 
clamp for 5 minutes (preload time) to establish 
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adhesion bonding between disc and palatal 
mucosa. The preload and preload time were kept 
constant for all the formulations. After 
completion of the preload time, preload was 
removed from the clamp, and the weight were 
placed on the another pan starting from 10 gm 
and the continousally increased the weight untill 
disc was detached mucosa. The weight required 
to detach disc from mucosa was noted as force of 
mucoadhesion, and these experiments were 
repeated three times with fresh mucosa in an 
identical manner for each formulation of F1- F15 
batch no. 
                                                  
Mucoadhesive strength  
Force of adhesion = --------------------------- * 9.81 
                                             100  
 
In Vitro Mucoretentability Measurement 
Mucoretentability property measured in terms of 
duration of time in which the disc is detached 
from to the mucus.  The in vitro 
mucoretentability studies were conducted using a 
dissolution apparatus assembly. Prepared disc of 
given polymer  was lowered onto the  palatal 
mucosa which is  already adhered  to the lower 
tip of basket and studies carried out at 150 rpm 
and 37 0C to simulate saliva movement [23] . The 
time necessary for complete erosion or 
detachment was taken as an indication of the in 
vitro adhesion time. 
 
In Vitro Dissolution Study 
In vitro dissolution study was carried out in a 
basket type dissolution test apparatus (TDT-06P, 
Electrolab, India) with stirring speed of 150 rpm 
using 900 ml Phosphate buffer pH 7.4 as 
dissolution medium under sink conditions. 
Prepared disks of RZM were added to dissolution 
medium kept at 37±0.5°C. Periodically, 5 ml  
solution withdrawn from the dissolution medium, 
Same volume of dissolution medium was 
replaced back after each sampling in order to 
maintain sink condition. Concentration of drug 
was determined using uv spectroscopy. After the 
dissolution study, disks were dried at room 
temperature and observed under the SEM to 
examine any changes in surface topography. .  
The drug release data obtained from the release 
rates were also evaluated by fitting into different 
kinetic models. 
 
Scanning electron microscopy 
Prepared disks obtained before and  after 
complete dissolution of core content were 
examined for their porous structure and 
topography using F 3000N SEM (Hitachi, Japan). 
After dissolution, disks were dried at 500C for 8 
hours and stored in dessicator before examination 
. disks were sputter coated for 5 to 10 minutes 
with gold by using fine coat ion sputter (Hitachi 
E-100, Japan ) and examined under SEM. 
 
Histology of isolated palatal tissue 
The histology of the isolated tissue before and 
after in vitro mucoretentability was examined by 
photomicroscopy At the end of in vitro 
mucoretentability study [24], the disks was 
removed from the isolated tissue. Then tissue was 
taken and after a classical fixation, dehydration 
and embedding procedure [25], sections were cut, 
stained with eosin and examined under a light 
microscope (Nikon, Japan).  
 
Results and discussions 
RZM belongs to class 1 drugs of 
Biopharmaceutical Classification System [26]. 
The drug is highly soluble in aqueous solution at 
pH1.2. So a good release retardant is necessary to 
control the release of RZM from the 
mucoadhesive disk, by the use of mucoadhesive 
polymers the active ingredient is released slowly 
by diffusion. It shows pH-independent release 
profile, which means that drug release takes place 
independently of individual variation. For this 
reason, these mucoadhesive polymers have been 
used to prolong RZM release from the 
mucoadhesive disks formulation.  
 
Disks Formation and Morphology 
Mucoadhesive disks were prepared by direct 
compression method. The surface structure of the 
disks produced by the direct compression method 
was found spherical as observed visually  
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   1(a)                                                                                                                     1 (b) 
AV = 15 KV                                    Mag = 
400 X 
AV = 15 KV                                          
Mag = 400 X 
Fig: 1- Scanning electron micrograph of disks  (a) before and (b) after dissolution 
 
 
Fig. 2. In vitro drug dissolution profile of mucoadhesive disks. 
 
 
                                        
Fig-3a                                                                             Fig-3b 
Fig-3 Palatal mucosa before and after in vitro mucoretentability study 
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Table 1.  Simplex lattice design for various formulations. 
               Polymer compositions (mg) Excipients (mg) Formulae Drug 
(mg) CP SCMC HPMCK4M Guar Gum DPP PEG Mannitol
F1 
F2 
F3 
F4 
F5 
F6 
F7 
F8 
F9 
F10 
F11 
F12 
F13 
F14 
F15 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
100 
- 
- 
- 
50 
50 
50 
- 
- 
- 
33.3 
33.3 
33.3 
- 
25 
- 
100 
- 
- 
50 
- 
- 
50 
50 
- 
33.3 
33.3 
- 
33.3 
25 
- 
- 
100 
- 
 
50 
- 
50 
- 
50 
- 
33.3 
33.3 
33.3 
25 
- 
- 
- 
100 
- 
- 
50 
- 
50 
50 
33.3 
 
33.3 
33.3 
25 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
15 
 
Table. 2. Observation of drug excipient compatibility study 
Discoloration    Caking Liquefication    Mixture   Rf 
value 
 1:1 1:10 1:1 1:10 1:1 1:10 
Drug:SCMC 0.46   -   -       -       -        -        - 
Drug:HPMCK4M 0.46   -   -       -       -        -          - 
Drug: Carbopol 0.46   -   -       -       -        -        - 
Drug:  Guar Gum 0.46       -       -       -        -       -       - 
Drug:  Date palm polymer 0.46       -       -       -        -       -       - 
Drug:  PEG 0.46   -   -       -       -        -        - 
Drug:  Mannitol 0.46   -   -       -       -        -          - 
-  Compatible                    + Incompatible 
 
Table-3 In Vitro Mucoadhesive strength (Mean adhesive force %)  and  Adhesion Time of RZM Mucoadhesive Palatal D 
iscs. 
Formulation F1 F2 F3 F4 F5 F6 F7 F8 F9 F11 F12 F14 
Mean 
Adhesive 
Force (%) 
2.68 ± 
0.065 
2.57 ± 
0.090 
1.69 ± 
0.037 
2.28 ± 
0.037 
3.15 ± 
0.026 
2.07 ± 
0.020 
2.38 ± 
0.142 
2.05 ± 
0.023 
1.97 ± 
0.020 
3.02 ± 
0.060 
3.51 ± 
0.020 
1.88 ± 
0.011 
In vitro 
Adhesion 
time (Hrs) 
13.24±
0.035 
13.14±
0.045 
8.06±
0.015 
11.53±
0.028 
16.42±
0.025 
11.32±
0.025 
12.47±
0.025 
11.47±
0.025 
11.37±
0.026 
14.39±
0.096 
18.44±
0.045 
10.54±
0.015 
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(Fig.1a). The surface of the disks was smooth and 
revealed the presence of larger pores in disks 
after dissolution which, in part, might be 
responsible for their drug release behaviour 
(Fig.1b). Before and after the dissolution study, 
disks were dried, and observed under the SEM. 
SEM revealed that the disks retained their size 
intact. They were spherical in nature with smooth 
surface. There is no significant change in their 
surface topography  
 
Drug–Excipient Interaction Study 
Drug excipient compatibility was performed by 
using binary mixture approach. Physical mixtures 
were observed for 2 weeks and the results 
obtained are listed in table 2. Results showed that 
drug was found to be compatible with the 
selected polymers. 
 
Physical Characterization of Mucoadhesive 
Palatal Discs 
Friability test was applied to palatal discs 
prepared by direct compression. Several 
preliminary experiments were done to prepare 
RZM palatal discs containing several 
combinations of different polymers. Cp, HPMC, 
SCMC, Guar Gum, DPP   were used to prepare 
palatal discs in different ratio (table 1). The 
friability test was conducted for all prepared 
formulae. All formulation showed friability 
values well below the 1% tolerance limit set by 
the British Pharmacopoeia for pharmaceutical 
tablets. except for the formulation F10, F13,F15 
These formulae, having friability values above 
the 1% tolerance limit, were excluded. Disc 
thickness ranges of the discs prepared by direct 
compression were 1.82 – 1.98 mm. Disc weight 
ranges of the discs prepared by direct 
compression were 147– 152 mg. The RZM 
content was determined for each palatal disc. It 
was found that the RZM content in all palatal 
discs was in the range from 9.20 to 10.22 mg. 
 
 
Adhesion Time and Force of adhesion of RZM 
Mucoadhesive Palatal Discs  
Palatal discs showed (Table-3) adhesion time 
ranging from 8.06 ±0.015 h for formula (F3) to 
18.44±0.45 h for formula (F12) and force of 
adhesion ranging from 1.690N to 3.515N.  The 
results revealed that the formulation F3, 
F4,F6,F8,F9 were not able to retain the 
formulation upto 12 hr and  F10, F13,F15 These 
formulation, having friability values above the 
1% tolerance limit, were excluded  for in vitro 
mucoadhesive and in vitro mucoretentability 
study. 
 
In Vitro drug Release and Kinetic Analysis of 
the Release Data of RZM from Different 
palatal Discs 
The release of RZM from the various 
mucoadhesive polymers (Cp, SCMC, HPMC, 
Guar Gum, DPP in different ratio) and drug in 
different combinations as per simplex lattice 
design  prepared by direct compression was 
studied (Fig. 2). Excipients like polyethylene 
glycol (PEG 6000) and mannitol were used to 
develop a palatal disc to ensure drug release in 
the palatal mucosa. It was reported that PEG 
6000 could increase the release of drugs from the 
matrix and that mannitol had a sweet taste, a 
good mouth feel, negative heat of solution, and 
dissolution enhancing properties [27]. The effect 
of drug/polymer ratio and polymer/polymer ratio 
on the RZM release properties from the palatal 
discs prepared by direct compression with 
different polymer combinations was studied 
through validated PCP disso v2 08 soft ware 
(Poona College of Pharmacy, Pune, India). For 
most of the tested formulations, the values of n 
were >0.05, indicating anomalous (non-Fickian) 
diffusion where drug release is controlled by a 
combination of diffusion and polymer relaxation. 
.The release profiles up to 12 hrs of RZM from 
all formulations in the dissolution medium were 
statistically compared with each other by the help 
of statistical test one way ANOVA and 
nonparametric kruskal wallis test by using Graph 
pad Prism version 5 software. Results of 
statistical test  showed that there was no 
significant difference in RZM release from all the 
formulations at 95% confidence interval with  the 
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calculated  F – value (1.255< 2.18)  was found to 
be less than tabled F-value and F11 formulation 
has been selected as best formulation, as it 
follows the zero order drug release kinetics with  
R=0.9844 value and n=0.9063 (n>0.05) , which 
means that the release of RZM from F11 
formulation is of anamalous type moreover it also 
follows the criteria of USP standard that there 
should be at least 80% release from formulation 
in the prescribed time. 
 
Kinetic models of Drug Release 
All the models for selecting the release profile 
were applied on all the formulations. Release 
models were applied on the selected formulation. 
Results showed that best fit model in all the case 
except F-2 could have followed the Zero order, 
first order, Matrix, peppas, Hixon crowell model 
and the Peppas and corsenmayer model. While 
considering higher correlation coefficient value 
(R), the release data seems to fit Peppas model 
better.  According to correlation coefficient value 
(R)   and maximum drug release with good 
mucoretentability F-11 seems to be the best 
formulation.  Drug release data, For F-11 
formulation further analyzed for curve fitting  
based on Power law and results (F-11: n = 
0.9063, k = 0.0090, and R=0.9844) confirmed 
that release of RZM from F-11 formulation is of 
anamalous type. 
 
Histological studies 
Disks remained attached to the palatal mucosa 
during the 12 h period without any disintegration.  
Typical appearance of intact palatal mucosa is 
seen in Fig. 3a. After 12 h contact with the disks 
the surface layer of the mucosa was not smooth 
as the intact mucosa, showing a slight irregularity 
in Fig. 3b.  
 
Conclusion 
It may be concluded that that optimized 
formulation (F11) was selected as the 
finaloptimized formulation that exhibited less 
percentage deviation of drug release. The 
mechanism of release of rosiglitazone maleate 
from the mucoadhesive dosage form was 
following zero order as well as anamolous type. 
Hence, in the present study mucoadhesive 
rosiglitazone disks could be developed with 
desirable mucoadhesion and release modulation 
for a once daily administration. 
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